-
Mashup Score: 66
By Annalisa Paviglianiti, Tânia Maia & 15 more. Patients with a low ALC on day +30 face a higher risk of HHV6 reactivation and may require careful monitoring.
Source: chi.scholasticahq.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 60Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft - 3 month(s) ago
Post-transplantation cyclophosphamide (PTCy) is an effective strategy for graft-versus-host disease (GVHD) prophylaxis and is the standard of care for…
Source: www.sciencedirect.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Paper: Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy - 4 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Clinical an d Epidemiological: Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Hematology Disease Topics & Pathways: Research, adult, elderly, non-Hodgkin lymphoma, Lymphomas, epidemiology, B Cell lymphoma, Clinical Research, Diseases, aggressive lymphoma, real-world evidence, Lymphoid Malignancies, Study Population, Human Steven M. Bair, MD 1, Mayur Narkhede, MD 2 *, Zachary AK Frosch, MD, MSHP 3,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy Hematology Disease Topics & Pathways: clinical trials, Research, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Research, drug development, Diseases, indolent lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies Lorenzo Falchi, MD 1, Michelle Okwali, MPH 1 *, Paola Ghione, MD, MSEpi 2,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5Paper: Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Hematology Disease Topics & Pathways: Research, clinical trials, Lymphomas, non-Hodgkin lymphoma, Clinical Research, Combination therapy, Diseases, indolent lymphoma, Therapies, Lymphoid Malignancies Loic Ysebaert, MD, PhD 1 *, Francois Lemonnier 2 *, Gabriel Brisou 3 *,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Paper: CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Aiming for the Right Target: Using CAR-T and Bispecifics in Aggressive Lymphomas Eric Durot 1 *, Damien Roos-Weil 2 *, Adrien Chauchet 3 *, Justine Decroocq, MD 4 *, Roberta Di Blasi, MD, PhD 5 *, Thomas Gastinne, MD 6 *, Hedi Bensader 7 *, Morgane Cheminant 8 *, Caroline Jacquet, MD 9 *, Stephanie Guidez 10 *, François-Xavier Gros 11 *, Emmanuel Bachy, MD, PhD 12 *, Pascale Cony-Makhoul, MD 13
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 0
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy Hematology Disease Topics & Pathways: clinical trials, Research, Biological therapies, Lymphomas, non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Research, drug development, Diseases, indolent lymphoma, Therapies, Immunotherapy, Lymphoid Malignancies Lorenzo Falchi, MD 1, Michelle Okwali, MPH 1 *, Paola Ghione, MD, MSEpi 2,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 5Paper: Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Hematology Disease Topics & Pathways: Research, clinical trials, Lymphomas, non-Hodgkin lymphoma, Clinical Research, Combination therapy, Diseases, indolent lymphoma, Therapies, Lymphoid Malignancies Loic Ysebaert, MD, PhD 1 *, Francois Lemonnier 2 *, Gabriel Brisou 3 *,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 2Paper: Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Hematology Disease Topics & Pathways: adult, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, Diseases, indolent lymphoma, Lymphoid Malignancies, Study Population, Human Loic Ysebaert, MD, PhD 1 *, Roch Houot, MD, PhD 2 *, Olivier Casasnovas,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 3Paper: Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 621. Lymphomas: Translational – Molecular and Genetic: Microenvironment and Methylome in Lymphoma and Misc. Hematology Disease Topics & Pathways: Research, clinical trials, Lymphomas, non-Hodgkin lymphoma, Non-Biological therapies, assays, Clinical Research, B Cell lymphoma, Chemotherapy, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Technology and Procedures, molecular testing Fabrice Jardin, MD PhD 1 *, Vibha Raghavan, MSc 2 *,
Source: ash.confex.comCategories: General Medicine News, Hematologists1Tweet
Finally out! Happy to share our study on HHV6 reactivation after haploidentical HCT. Our findings endorse the safety of combining ATG and PTCy. The main risk factor for HHV6 reactivation was a low lymphocyte count at day 30 after HCT. ARTICLE👉https://t.co/wuXF7vZMEQ @Mohty_EBMT https://t.co/ispAozVtoE